Clinical trial
A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With RRMM Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
NCT03180736 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With RRMM Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
- Lead sponsor
- Stichting European Myeloma Network
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 14, 2017
- Completion date
- November 30, 2024
- Enrollment
- 304 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.